Yeow, Zhong Y.
Lambrus, Bramwell G.
Marlow, Rebecca
Zhan, Kevin H.
Durin, Mary-Anne http://orcid.org/0000-0003-4073-3463
Evans, Lauren T.
Scott, Phillip M.
Phan, Thao
Park, Elizabeth
Ruiz, Lorena A.
Moralli, Daniela http://orcid.org/0000-0001-7977-8496
Knight, Eleanor G.
Badder, Luned M.
Novo, Daniela
Haider, Syed http://orcid.org/0000-0001-6685-5480
Green, Catherine M.
Tutt, Andrew N. J.
Lord, Christopher J.
Chapman, J. Ross http://orcid.org/0000-0002-6477-4254
Holland, Andrew J. http://orcid.org/0000-0003-3728-6367
Article History
Received: 10 June 2019
Accepted: 17 June 2020
First Online: 9 September 2020
Competing interests
: C.J.L. received research funding from AstraZeneca, Merck KGaA and Artios; received consultancy, SAB membership or honoraria payments from Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma and Artios; and has stock in Tango and Ovibio. None of these is directly relevant to the work published and/or discussed in this Article. C.J.L. is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from the development as part of the ICR Rewards to Inventors scheme. A.N.J.T received research funding from AstraZeneca and Merck KGaA that is not directly relevant to work published or discussed in this Article. A.N.J.T. also receives payments from the ICR Rewards to Inventors scheme associated with patents describing the use of DNA repair inhibitors and stands to gain from their development.